Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have earned a consensus recommendation of "Buy" from the fourteen ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.7692.
A number of brokerages have commented on TSHA. Robert W. Baird lifted their target price on Taysha Gene Therapies from $12.00 to $15.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. Citizens Jmp restated a "market outperform" rating and set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. The Goldman Sachs Group upped their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. BMO Capital Markets raised their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an "outperform" rating in a research note on Tuesday, June 23rd. Finally, Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd.
Check Out Our Latest Stock Report on TSHA
Taysha Gene Therapies Stock Up 4.4%
Shares of NASDAQ:TSHA opened at $6.21 on Tuesday. The company's fifty day moving average is $6.12 and its two-hundred day moving average is $5.50. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76. Taysha Gene Therapies has a 1-year low of $2.71 and a 1-year high of $7.30. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -14.79 and a beta of 1.22.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts anticipate that Taysha Gene Therapies will post -0.51 EPS for the current year.
Insiders Place Their Bets
In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider directly owned 936,410 shares in the company, valued at $5,843,198.40. This trade represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Caitong International Asset Management Co. Ltd raised its holdings in shares of Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock valued at $43,000 after buying an additional 4,607 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Taysha Gene Therapies in the 4th quarter worth approximately $59,000. Guggenheim Capital LLC bought a new position in Taysha Gene Therapies in the 4th quarter worth approximately $61,000. R Squared Ltd bought a new position in Taysha Gene Therapies in the 1st quarter worth approximately $50,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Taysha Gene Therapies in the 1st quarter valued at approximately $51,000. Institutional investors own 77.70% of the company's stock.
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
